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March 21, 2006:1226–38ize measurement is well-established (4) on the basis of multiple
ines of scientific evidence. We agree that myocardium at risk is
ighly variable and a major determinant of infarct size in both
nimal models and humans. The absence of measurement of
yocardium at risk will reduce power (i.e., increase the likelihood
f a type II [beta] statistical error). However, the estimates
eported in our paper of a type I (alpha) statistical error for infarct
ize remain valid. In the AMISTAD I study (5), myocardium at
isk was measured in a subset of patients. In anterior infarcts,
denosine showed similar benefit using either myocardial salvage
ndex (p  0.015) or infarct size (p  0.014). Other randomized
rials that have measured myocardium at risk and infarct size (6,7)
ave reported similar significant differences using either infarct size
r salvage index as an end point.
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tatins and Antioxidant Vitamins:
hould Co-Administration Be Avoided?
n the interesting study by Arad et al. (1), co-administration of
torvastatin (20 mg/day) and high-dose antioxidant vitamins C (1 g/
ay) and E (1,000 IU/day) failed to decrease the progression of
oronary calcification, whereas a borderline decrease of cardiovas- rular events was observed. Based on the fact that previous studies
ave shown that statins do decrease both the progression of
oronary artery calcification and cardiovascular events (2), the
nvestigators proposed that the atorvastatin dosage they used was
ow, and they suggested that their population was not large enough
o detect any differences. However, another possibility might be
onsidered: The results of the present study may reflect a negative
ffect of antioxidant vitamins (especially vitamins C and E), which
ould interfere with lipoprotein metabolism, preventing the statin-
nduced increase of high-density lipoprotein (HDL)-2 subfraction,
s has been proposed in the past (3). Indeed, in a study by Brown
t al. (4), it was shown that co-administration of statin and
ntioxidant vitamins C and E partly prevents the beneficial effects
f statins on cardiovascular outcome. Additionally, we (5) have
ecently demonstrated that, although low-dose atorvastatin treat-
ent (10 mg/day) improves endothelial function in patients with
schemic heart disease, this effect is abolished when vitamin E (400
U/day) is co-administered. Therefore, further studies examining
he effect of atorvastatin 10 to 20 mg/day alone on the progression
f coronary artery calcification and clinical events rate are required
efore any conclusion is made.
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EPLY
s Dr. Tousoulis and colleagues point out, the design of the St.
rancis Heart Study Randomized Clinical Trial (two cells of a 2
factorial) does not permit a definitive conclusion as to whether
tatins alone retard the progression of coronary calcification.
owever, there are other reasons to believe that statins do noteduce the rate of coronary calcification, or, if they do, that said
